Insider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) COO Sells 630 Shares of Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 630 shares of the company's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $250.87, for a total transaction of $158,048.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Xiaobin Wu also recently made the following trade(s):

• On Monday, June 16th, Xiaobin Wu sold 1,543 shares of BeOne Medicines stock. The stock was sold at an average price of $265.52, for a total transaction of $409,697.36.
• On Friday, June 6th, Xiaobin Wu sold 1,934 shares of BeOne Medicines stock. The stock was sold at an average price of $253.15, for a total value of $489,592.10.
• On Tuesday, April 1st, Xiaobin Wu sold 51,921 shares of BeOne Medicines stock. The shares were sold at an average price of $281.40, for a total value of $14,610,569.40.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC traded down $1.31 during trading on Wednesday, reaching $252.78. 230,441 shares of the company's stock traded hands, compared to its average volume of 447,828. The stock has a market cap of $27.69 billion, a PE ratio of -67.95 and a beta of 0.30. BeOne Medicines Ltd. - Sponsored ADR has a 12 month low of $141.31 and a 12 month high of $287.88. The company's 50 day moving average is $243.44. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The business had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.12 billion. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. Equities research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on ONC shares. JMP Securities set a $348.00 price target on shares of BeOne Medicines in a research report on Friday, February 28th. Bank of America raised shares of BeOne Medicines from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. Macquarie increased their price target on shares of BeOne Medicines from $259.00 to $313.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Royal Bank Of Canada lowered their price objective on BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Finally, TD Securities reaffirmed a "buy" rating and set a $334.00 target price on shares of BeOne Medicines in a report on Thursday, April 24th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, BeOne Medicines has a consensus rating of "Buy" and an average price target of $319.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.